"Functional T-Cell Changes: Aging, CMV Influence.": History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Fakhri Hassouneh
,
David Goldeck
,
Alejandra Pera
,
Diana van Heemst
,
P. Eline Slagboom
,
Graham Pawelec
,
Rafael Solana

Cytomegalovirus (CMV) latent infection and aging contribute to alterations in the function and phenotype of the T-cell pool. Researchers have demonstrated that CMV-seropositivity is associated with the expansion of polyfunctional CD57+ T-cells in young and middle-aged individuals in response to different stimuli. Researchers expand their results on the effects of age and CMV infection on T-cell functionality in a cohort of healthy middle-aged and older individuals stratified by CMV serostatus. Specifically, researchers studied the polyfunctional responses (degranulation, IFN-γ and TNF-α production) of CD4+, CD8+, CD8+CD56+ (NKT-like), and CD4-CD8- (DN) T-cells according to CD57 expression in response to Staphylococcal Enterotoxin B (SEB). 

  • aging
  • cytomegalovirus
  • CD57
  • T-cell response

 1. Introduction

The human immune system evolved to protect and defend the organism against disease and potentially to protect the symbiotic gut microbiota. T-cells are a major component of adaptive immunity, with a high degree of specificity in response to a pathogen challenge, enabling the host to mount a specific immune response and generate immunological memory [1]. Therefore, for effective immune protection against the primary and subsequent challenges, these cells must be maintained in a unimpaired state and appropriately regulated [2]. However, on aging, the immune system undergoes profound changes, loosely termed immunosenescence, that can affect the outcome of the immune response [3]. The impact of these age-related changes on the immune system has been associated clinically with decreased efficacy of vaccines, an increase in the frequency and severity of infectious diseases, and an increased incidence of chronic inflammatory disorders [3][4]. These alterations are associated with phenotypical and functional changes affecting a variety of immune cells, especially T-cells [5][6]. It has been shown that chronic stimulation of the immune system, such as by persistent viral infections, associates with age-related alterations in the peripheral T-cell pool [7]. Chronic infection especially by cytomegalovirus (CMV) has a dramatic influence on the T-cell compartment, both on CD8+ and CD4+ T-cells [8][9]. CMV interferes with different aspects of immune responses, and HLA, KIR, and GM genes have been shown to play a crucial role in CMV control (for review, see [10]). Recent epidemics of emerging pathogens that have a differential immune response depending on age, such as SARS-CoV-2, illustrate the crucial importance to understand the basis of an adequate response to new antigens and the relevance of factors such as age or CMV infection.

2. Current Insight on Functional Changes of T-Cell Subsets 

In humans, repetitive replication of T-cells is associated with the loss of CD28 and the acquisition of CD57. Thus, CD28− and CD57+ T-cells are considered to be late- or terminally differentiated T-cells characterized by low telomerase activity and shorter telomeres compared with CD28+CD57− T-cells. At least some of these CD28-CD57+ T-cells may be senescent [11][12]. It has been shown that besides age, persistent CMV infection is also associated with the accumulation of these highly differentiated T-cells [13][14]. Accumulating evidence supports a detrimental role of senescent T-cells in several chronic inflammatory clinical conditions, including cardiovascular diseases such as atherosclerosis and myocardial infarction (for a review, see [15][16]).
Our results show that in middle-aged and older overtly healthy individuals, the main factor driving the expansion of CD57+ T-cells is CMV infection. However, from the fourth decade onwards, these cells do not accumulate further with age. In previous work, researchers showed that the percentage of CD8+CD57+ T-cells was similar between young and middle-aged CMV-seropositive individuals [17]. Therefore, here, researchers extend their previous findings [17][18][19][20] to show that CD57 expression by T-cells is not only a hallmark of CMV infection in young individuals but also at older ages. Accordingly, once CMV infection takes place, CD57+ T-cells will expand, and after that, their percentage will remain rather stable over time. Thus, their results argue against the consensus that the expansion of these cells is a sign of chronological aging.
Regarding CD57+ T-cell functional capacities, their data also indicate that CD57+ T-cells are more polyfunctional than CD57− T-cells at any age, with one exception, namely the DN T-cell subset, where the PI does not change with CD57 expression. Nonetheless, researchers did observe an increase in trifunctional DN T-cells with CMV seropositivity, and the total PI of DN T-cells increased with CMV infection in middle-aged individuals. In this subset, CD57+ T-cells also accumulate in CMV-seropositive individuals.
Our results regarding CD4+CD57+ T-cell expansions with CMV infection are also in agreement with the observation that CMV, but not aging, has a significant effect on the expansion of pro-atherogenic CD4+CD28− T-cells [21]. These cells (that also express CD57) are cytotoxic, capable of causing vascular damage, and their expansion is associated with autoimmune and cardiovascular disease (for a review, see [15][16]). Here, researchers show that similar to young individuals [18], at older ages, CD4+CD57+ T-cells are also more polyfunctional (CD107a, IFN-γ, and TNF-α) than their CD57− counterparts. Additionally, the percentage of these polyfunctional cells correlated with the percentage of total CD4+CD107a+ (i.e., cytotoxic) T-cells (Spearman correlation p-value = 0.03, Figure S4). Notably, CMV-seronegative individuals had very low or no percentages of both cytotoxic CD4+ T-cells (CD1017a+) and CD4+CD57+ T-cells, supporting the conclusion that the expansion of cytotoxic CD4+ T-cells only occurs with CMV infection.
Higher frequencies of CD4+CD57+ T-cells have been associated with poorer prognosis in several diseases. In acute heart failure patients, high percentages of these cells are associated with the development of cardiovascular events (defined as heart failure-associated mortality, transplantation, or rehospitalization) [22]. In end-stage renal disease patients, the frequency of CD4+CD57+ T-cells is associated with atherosclerotic changes [23], and in multiple sclerosis, their frequency is associated with disease severity and poorer prognosis [24]. In addition, in acute heart failure patients, percentages of IFN-γ+ and TNF-α+cells are higher within the CD4+CD57+ than the CD57− T-cell subset, and CD4+CD57+IFN-γ+T-cells were increased in patients compared with healthy individuals in response to anti-CD3 stimulation [22]. The PI of CD4+ T-cells overall and the CD4+CD57+ T-cell fraction increased with CMV-seropositivity, but not age, supporting a significant role of CMV in the development of cardiovascular disease that can be explained, at least in part, through the expansion of these proinflammatory and cytotoxic CD4+CD57+ T-cells. Consistent with this, a link between CMV infection, CD4+CD28− T-cell expansions, and autoimmune and cardiovascular disorders has been previously suggested [15][25].
Our data may be of some practical clinical importance because CMV infection can be treated, and the expansion of these cytotoxic proinflammatory cells could potentially be prevented. In this respect, the use of Valacyclovir as anti-CMV treatment in patients with Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis was shown not only to suppress CMV reactivation but was also associated with a reduction of the CD4+CD28− T-cell frequency. Moreover, in a different context, a lower frequency of these cells correlated with improved responses to pneumococcal vaccination [26]. These results strongly suggest that the CMV-driven expansion of CD4+CD28−T-cells, and by extension CD4+CD57+ T-cells, might have a detrimental effect on the immune response to vaccination. These results, together with the proof of principle of the potential benefit of using anti-CMV treatments in ANCA-Associated Vasculitis, support the possible application of anti-CMV therapy in any clinical situation where CD4+CD57+ T-cells are implicated, including impaired responses to infection and vaccination.
Our results show that CD8+CD57+ T-cells are also expanded in CMV-seropositive individuals, both middle-aged and older. As in CD4+ T-cells, the expression of CD57 was associated with higher polyfunctionality determined by the PI value, this increase in the polyfunctionality of CD4+ and CD8+ T-cells being a hallmark of CMV infection. Indeed, it has been shown that CMV-specific CD8+ T-cells that produce IFN-γ and TNF-α as well as express CD107a play an important role in controlling this viral infection in the context of allogeneic stem cell transplantation [27]. Similarly, CMV-specific CD107a+IFN-γ+CD8+ T-cells are important for controlling CMV infection in rhesus macaques [28].
The expansion of CD8+CD57+ T lymphocytes is associated with CMV viremia in solid organ transplantation. These cells were characterized by IFN-γ and granzyme B production, and their expansion was associated with CMV-specific immune responses in pediatric cardiac transplantation [29]. Moreover, in renal transplant recipients, CMV induced the expansion of highly functional memory CD57+ T-cells [30], and during active CMV replication, highly differentiated CD8+CD57+ T-cells acquire cytotoxic activity [30]. Additionally, the frequency of total CD8+CD28− T-cells has been related to the specific immune response to CMV one year after solid organ transplantation [31].
As has been pointed out before, the effects of CMV infection and age differ among T-cell subsets. As reported here, CD4+ and CD8+ T-cells display a functional shift associated with CMV seropositivity, while NKT-like and DN T-cell subsets do not. Specifically, NKT-like cell functionality was not affected either by age or CMV, while DN T-cells’ response to SEB and PI was mainly altered by age. In individuals over 65 years of age, the impact of CMV infection on DN T-cell functionality seems to be diluted by the effect of aging.
The increased PI of DN T-cells with age seems to be due to a gain in cytotoxicity (CD107a marker of degranulation) rather than to higher cytokine production. DN T-cells are mainly gamma-delta T lymphocytes, and studies on the effect of its aging have yielded disparate results [32][33][34][35]. CMV does not stimulate Vdelta2+ cells, but it does stimulate Vdelta2− T-cells. These are characterized by the accumulation of highly differentiated Vδ2− subsets with time, in contrast to Vδ2+ T-cells, which are decreased in old individuals independently of CMV serostatus and maintain a less differentiated phenotype [32]. Although a limitation of their study is that researchers have not characterized the different gamma-delta subsets within the DN T-cells, their results clearly show a higher capacity of degranulation of these cells in older adults, independent of CMV serostatus.
It has been reported that NKT-like cells expand with age and in certain disease states. Their previous work [19][20] showed that in CMV-seropositive individuals of up to 60 years of age, there was no effect of age on the expansion of these cells. Researchers only observed an increase in NKT-like cell percentages when comparing young CMV-seronegative individuals and middle-aged CMV-seropositive individuals, indicating that CMV is an important factor for their expansion. However, there was no increase in NKT-like cell frequency with CMV in young individuals. To shed light on whether their accumulation is due to CMV infection alone or a combined effect with chronological aging, researchers analyzed the percentage of this cell subset at older age. Their results demonstrate that NKT-like cells expand in CMV-seropositive individuals over the age of 40 and onwards, and that age per se had no effect on their accumulation. Furthermore, researchers have also observed a significant expansion of NKT-like CD57+ cells in CMV-seropositive individuals, which is unrelated to aging. Earlier reports have shown heterogeneous results regarding the possible effect of aging on the number and function of NKT-like cells [36]. In the present study, researchers show that NKT-like cells accumulate from middle age onwards with CMV infection but not age alone, although no functional alterations were observed in this subset. These results are in contrast to other studies showing a higher functionality of CD56+ T-cells (determined by levels of CD107a and proinflammatory cytokines) in CMV-seropositive individuals [37]. These differences could be due to the fact that the age of the young group ranged from 23 to 60 years old in that study.
CMV infection induces the expansion of CD57+ T-cells, but whether this has a beneficial or detrimental or neutral role for immunity and long-term effects on health and its direct effect on response to pathogens and vaccines is still under debate. Nevertheless, there is mounting evidence that CMV-seropositivity is associated with a reduced response to both invasion with a novel pathogen and to vaccination Some studies have reported a beneficial effect of CMV infection in both young and older adults in response to vaccination [38][39], while other studies suggest that it can be detrimental [40][41]. The increased functionality of CD57+CD4+ and CD57+CD8+ T-cells shown can be considered beneficial, but under certain pathological conditions, CD57+ T-cells have immunosuppressive activity [42][43]. Thus, it is essential to further investigate the effects of CMV on the immune response at older ages. In this regard, their present study complements their previous investigations allowing researchers to dissect the effect of age and CMV in older individuals. This is especially important for vaccine development, as it has been shown for the influenza vaccines Fluad® or Intanza®, especially designed for elderly individuals [44][45]. A poor response to Intanza® was associated with CMV seropositivity, but only in older individuals [44][46]. In addition, it has been shown that older CMV-seropositive individuals have lower frequencies of influenza specific memory T-cells than CMV-seronegative, but this was not observed in younger individuals [47]. However, despite the lower frequencies of influenza-specific T-cells found in CMV-seropositive older individuals, they exhibited a significantly higher IFNγ T-cell response to influenza virus in the acute phase of the disease compared to CMV-seronegative older individuals [47]. These results agree with their results showing an increased polyfunctionality of CD4 and CD8 T-cells with CMV-seropositivity in older donors.
Our results regarding CD57+ T-cells expansion in CMV-seropositive older donors are also of interest in the study of CMV infection in transplant recipients where CMV infection represents a significant complication. CD8+CD57+ TEMRA cells increased over time after transplant specifically in CMV-seropositive but not CMV-seronegative recipients, and changes in CD8+ T-cells compatible with accelerated immune aging have been observed in CMV-seropositive transplant recipients [48]. Their results showing that CD57+ T-cells are mainly expanded in CMV-seropositive individuals, and maintain cytokine production and polyfunctionality independently of age, suggest that CD57+ T-cells may contribute to the promotion of adverse inflammatory outcomes, such as late graft dysfunction, chronic kidney rejection, cancer, and atherosclerosis observed after kidney transplant associated with CMV infection.
The results presented also highlight the relevance of considering the heterogeneity of CMV seropositivity and aging in the design of clinical trials or new vaccines in some clinical conditions such in HIV patients. Thus, CMV-induced chronic immune activation and premature immunosenescence in people living with HIV must be taken into consideration not only when comparing trial outcomes between various populations exhibiting diverse CMV positivity rates but also for HIV vaccine development [49].
Therefore, immunological treatments should consider both age and CMV infection as a major factor. This strengthens the need for validation studies with not only the aim to present something novel but also to confirm findings in different populations.
Our results support the view that CMV is a major driving force for the expansion of CD57+ T-cells, and that these cells are more polyfunctional than their CD57-negative counterparts within the CD4+ and CD8+ subsets (including NKT-like cells). Age has no significant effect on either the frequencies of CD57+ T-cells or their polyfunctionality when only CMV seronegative individuals are considered. Thus, their results indicate that the CD57+ T-cell population might play an important role for antiviral control, which is in line with their high cytotoxic and polyfunctional activity. The association of these T-cell expansions with CMV infection and disease underlines the necessity of considering CMV serology in any study regarding immunosenescence and emphasizes that the price of immune protection is always some degree of immunopathology.

This entry is adapted from the peer-reviewed paper 10.3390/ijms22189973

References

  1. Bonilla, F.A.; Oettgen, H.C. Adaptive immunity. J. Allergy Clin. Immunol. 2010, 125, S33–S40.
  2. Farber, D.L.; Yudanin, N.A.; Restifo, N.P. Human memory T cells: Generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 2014, 14, 24–35.
  3. Pawelec, G.; Derhovanessian, E. Role of CMV in immune senescence. Virus Res. 2011, 157, 175–179.
  4. Pawelec, G.; Derhovanessian, E.; Larbi, A.; Strindhall, J.; Wikby, A. Cytomegalovirus and human immunosenescence. Rev. Med. Virol. 2009, 19, 47–56.
  5. Miller, R.A. The aging immune system: Primer and prospectus. Science 1996, 273, 70–74.
  6. Cambier, J. Immunosenescence: A problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol. Rev. 2005, 205, 5–6.
  7. Wertheimer, A.M.; Bennett, M.S.; Park, B.; Uhrlaub, J.L.; Martinez, C.; Pulko, V.; Currier, N.L.; Nikolich-Žugich, D.; Kaye, J.; Nikolich-Žugich, J. Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J. Immunol. 2014, 192, 2143–2155.
  8. Koch, S.; Solana, R.; Dela Rosa, O.; Pawelec, G. Human cytomegalovirus infection and T cell immunosenescence: A mini review. Mech. Ageing Dev. 2006, 127, 538–543.
  9. Koch, S.; Larbi, A.; Ozcelik, D.; Solana, R.; Gouttefangeas, C.; Attig, S.; Wikby, A.; Strindhall, J.; Franceschi, C.; Pawelec, G. Cytomegalovirus infection: A driving force in human T cell immunosenescence. Ann. N. Y. Acad. Sci. 2007, 1114, 23–35.
  10. Aiello, A.; Accardi, G.; Candore, G.; Caruso, C.; Colomba, C.; Di Bona, D.; Duro, G.; Gambino, C.M.; Ligotti, M.E.; Pandey, J.P. Role of Immunogenetics in the Outcome of HCMV Infection: Implications for Ageing. Int. J. Mol. Sci. 2019, 20, 685.
  11. Appay, V.; van Lier, R.A.; Sallusto, F.; Roederer, M. Phenotype and function of human T lymphocyte subsets: Consensus and issues. Cytom. A 2008, 73, 975–983.
  12. Koch, S.; Larbi, A.; Derhovanessian, E.; Ozcelik, D.; Naumova, E.; Pawelec, G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun. Ageing 2008, 5, 6.
  13. Elwenspoek, M.M.C.; Sias, K.; Hengesch, X.; Schaan, V.K.; Leenen, F.A.D.; Adams, P.; Meriaux, S.B.; Schmitz, S.; Bonnemberger, F.; Ewen, A.; et al. T Cell Immunosenescence after Early Life Adversity: Association with Cytomegalovirus Infection. Front. Immunol. 2017, 8, 1263.
  14. Focosi, D.; Bestagno, M.; Burrone, O.; Petrini, M. CD57+ T lymphocytes and functional immune deficiency. J. Leukoc. Biol. 2010, 87, 107–116.
  15. Broadley, I.; Pera, A.; Morrow, G.; Davies, K.A.; Kern, F. Expansions of Cytotoxic CD4. Front. Immunol. 2017, 8, 195.
  16. Pera, A.; Broadley, I.; Davies, K.A.; Kern, F. Cytomegalovirus as a Driver of Excess Cardiovascular Mortality in Rheumatoid Arthritis: A Red Herring or a Smoking Gun? Circ. Res. 2017, 120, 274–277.
  17. Pera, A.; Campos, C.; Corona, A.; Sanchez-Correa, B.; Tarazona, R.; Larbi, A.; Solana, R. CMV latent infection improves CD8+ T response to SEB due to expansion of polyfunctional CD57+ cells in young individuals. PLoS ONE 2014, 9, e88538.
  18. Pera, A.; Vasudev, A.; Tan, C.; Kared, H.; Solana, R.; Larbi, A. CMV induces expansion of highly polyfunctional CD4+ T cell subset coexpressing CD57 and CD154. J. Leukoc. Biol. 2017, 101, 555–566.
  19. Hassouneh, F.; Campos, C.; López-Sejas, N.; Alonso, C.; Tarazona, R.; Solana, R.; Pera, A. Effect of age and latent CMV infection on CD8+ CD56+ T cells (NKT-like) frequency and functionality. Mech. Ageing Dev. 2016, 158, 38–45.
  20. Hassouneh, F.; Lopez-Sejas, N.; Campos, C.; Sanchez-Correa, B.; Tarazona, R.; Solana, R.; Pera, A. Differential Effect of Cytomegalovirus Infection with Age on the Expression of CD57, CD300a, and CD161 on T-Cell Subpopulations. Front. Immunol. 2017, 8, 649.
  21. Pera, A.; Caserta, S.; Albanese, F.; Blowers, P.; Morrow, G.; Terrazzini, N.; Smith, H.E.; Rajkumar, C.; Reus, B.; Msonda, J.R.; et al. CD28. Theranostics 2018, 8, 4509–4519.
  22. Youn, J.C.; Jung, M.K.; Yu, H.T.; Kwon, J.S.; Kwak, J.E.; Park, S.H.; Kim, I.C.; Park, M.S.; Lee, S.K.; Choi, S.W.; et al. Increased frequency of CD4. Sci. Rep. 2019, 9, 12887.
  23. Okba, A.M.; Abd El Raouf Raafat, M.; Nazmy Farres, M.; Abd El Nour Melek, N.; Amin, M.M.; Gendy, N.N. Expanded peripheral CD4. Hum. Immunol. 2019, 80, 748–754.
  24. Peeters, L.M.; Vanheusden, M.; Somers, V.; Van Wijmeersch, B.; Stinissen, P.; Broux, B.; Hellings, N. Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression. Front. Immunol. 2017, 8, 1160.
  25. Bano, A.; Pera, A.; Almoukayed, A.; Clarke, T.H.S.; Kirmani, S.; Davies, K.A.; Kern, F. CD28. F1000Research 2019, 8, 179.
  26. Chanouzas, D.; Sagmeister, M.; Faustini, S.; Nightingale, P.; Richter, A.; Ferro, C.J.; Morgan, M.D.; Moss, P.; Harper, L. Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. J. Infect. Dis. 2019, 219, 234–244.
  27. Muñoz-Cobo, B.; Solano, C.; Benet, I.; Costa, E.; Remigia, M.J.; de la Cámara, R.; Nieto, J.; López, J.; Amat, P.; Garcia-Noblejas, A.; et al. Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. J. Med. Virol. 2012, 84, 259–267.
  28. Chan, K.S.; Kaur, A. Flow cytometric detection of degranulation reveals phenotypic heterogeneity of degranulating CMV-specific CD8+ T lymphocytes in rhesus macaques. J. Immunol. Methods 2007, 325, 20–34.
  29. Jacobsen, M.C.; Manunta, M.D.I.; Pincott, E.S.; Fenton, M.; Simpson, G.L.; Klein, N.J.; Burch, M. Specific Immunity to Cytomegalovirus in Pediatric Cardiac Transplantation. Transplantation 2018, 102, 1569–1575.
  30. Makwana, N.; Foley, B.; Fernandez, S.; Lee, S.; Irish, A.; Pircher, H.; Price, P. CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients. Eur. J. Immunol. 2017, 47, 1324–1334.
  31. Cantisán, S.; Páez-Vega, A.; Santos, F.; Rodríguez-Benot, A.; Aguado, R.; Rivero, A.; Montejo, M.; Torre-Cisneros, J.; Solana, R.; (REIPI), S.N.f.R.i.I.D. Impact of age and cytomegalovirus on CD8. Exp. Gerontol. 2017, 95, 98–106.
  32. Roux, A.; Mourin, G.; Larsen, M.; Fastenackels, S.; Urrutia, A.; Gorochov, G.; Autran, B.; Donner, C.; Sidi, D.; Sibony-Prat, J.; et al. Differential impact of age and cytomegalovirus infection on the γδ T cell compartment. J. Immunol. 2013, 191, 1300–1306.
  33. Vasudev, A.; Ying, C.T.; Ayyadhury, S.; Puan, K.J.; Andiappan, A.K.; Nyunt, M.S.; Shadan, N.B.; Mustafa, S.; Low, I.; Rotzschke, O.; et al. γ/δ T cell subsets in human aging using the classical α/β T cell model. J. Leukoc. Biol. 2014, 96, 647–655.
  34. Tan, C.T.; Wistuba-Hamprecht, K.; Xu, W.; Nyunt, M.S.; Vasudev, A.; Lee, B.T.; Pawelec, G.; Puan, K.J.; Rotzschke, O.; Ng, T.P.; et al. Vδ2+ and α/ß T cells show divergent trajectories during human aging. Oncotarget 2016, 7, 44906–44918.
  35. van der Geest, K.S.M.; Kroesen, B.J.; Horst, G.; Abdulahad, W.H.; Brouwer, E.; Boots, A.M.H. Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells. Front. Immunol. 2018, 9, 752.
  36. Mocchegiani, E.; Giacconi, R.; Cipriano, C.; Malavolta, M. NK and NKT cells in aging and longevity: Role of zinc and metallothioneins. J. Clin. Immunol. 2009, 29, 416–425.
  37. Almehmadi, M.; Flanagan, B.F.; Khan, N.; Alomar, S.; Christmas, S.E. Increased numbers and functional activity of CD56⁺ T cells in healthy cytomegalovirus positive subjects. Immunology 2014, 142, 258–268.
  38. Furman, D.; Jojic, V.; Sharma, S.; Shen-Orr, S.S.; Angel, C.J.; Onengut-Gumuscu, S.; Kidd, B.A.; Maecker, H.T.; Concannon, P.; Dekker, C.L.; et al. Cytomegalovirus infection enhances the immune response to influenza. Sci. Transl. Med. 2015, 7, 281.
  39. Miles, D.J.; Sanneh, M.; Holder, B.; Crozier, S.; Nyamweya, S.; Touray, E.S.; Palmero, M.S.; Zaman, S.M.; Rowland-Jones, S.; van der Sande, M.; et al. Cytomegalovirus infection induces T-cell differentiation without impairing antigen-specific responses in Gambian infants. Immunology 2008, 124, 388–400.
  40. Khan, N.; Shariff, N.; Cobbold, M.; Bruton, R.; Ainsworth, J.A.; Sinclair, A.J.; Nayak, L.; Moss, P.A. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol. 2002, 169, 1984–1992.
  41. Ouyang, Q.; Wagner, W.M.; Zheng, W.; Wikby, A.; Remarque, E.J.; Pawelec, G. Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly. Exp. Gerontol. 2004, 39, 607–613.
  42. Sadat-Sowti, B.; Debre, P.; Mollet, L.; Quint, L.; Hadida, F.; Leblond, V.; Bismuth, G.; Autran, B. An inhibitor of cytotoxic functions produced by CD8+CD57+ T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur. J. Immunol. 1994, 24, 2882–2888.
  43. Frassanito, M.A.; Silvestris, F.; Cafforio, P.; Dammacco, F. CD8+/CD57 cells and apoptosis suppress T-cell functions in multiple myeloma. Br. J. Haematol. 1998, 100, 469–477.
  44. Derhovanessian, E.; Theeten, H.; Hähnel, K.; Van Damme, P.; Cools, N.; Pawelec, G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine 2013, 31, 685–690.
  45. Goldeck, D.; Theeten, H.; Hassouneh, F.; Oettinger, L.; Wistuba-Hamprecht, K.; Cools, N.; Tsitsilonis, O.E.; Pawelec, G. Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine. Vaccine 2017, 35, 4330–4338.
  46. Derhovanessian, E.; Maier, A.B.; Hähnel, K.; McElhaney, J.E.; Slagboom, E.P.; Pawelec, G. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. J. Immunol. 2014, 193, 3624–3631.
  47. van den Berg, S.P.H.; Lanfermeijer, J.; Jacobi, R.H.J.; Hendriks, M.; Vos, M.; van Schuijlenburg, R.; Nanlohy, N.M.; Borghans, J.A.M.; van Beek, J.; van Baarle, D.; et al. Latent CMV Infection Is Associated with Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection. Front. Immunol. 2021, 12, 663664.
  48. Higdon, L.E.; Gustafson, C.E.; Ji, X.; Sahoo, M.K.; Pinsky, B.A.; Margulies, K.B.; Maecker, H.T.; Goronzy, J.; Maltzman, J.S. Association of Premature Immune Aging and Cytomegalovirus After Solid Organ Transplant. Front. Immunol. 2021, 12, 661551.
  49. Royston, L.; Isnard, S.; Lin, J.; Routy, J.P. Cytomegalovirus as an Uninvited Guest in the Response to Vaccines in People Living with HIV. Viruses 2021, 13, 1266.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback